# Prospective Analgesic Compound Efficacy (PACE) Study

> **NCT02403687** · — · COMPLETED · sponsor: **Express Specialty Pharmacy** · enrollment: 300 (actual)

## Conditions studied

- Arthritis
- Tendonitis
- Gout
- Radiculopathy
- Muscle Spasms
- Synovitis
- Migraine
- Headache

## Interventions

- **DRUG:** baclofen 2%
- **DRUG:** Bupivacaine hydrochloride 1%
- **DRUG:** Cyclobenzaprine hydrochloride 2%
- **DRUG:** Diclofenac Sodium 3%
- **DRUG:** Flurbiprofen 10%
- **DRUG:** Gabapentin 6%
- **DRUG:** Ketamine 10%
- **DRUG:** Lidocaine 2%
- **DRUG:** Prilocaine 2.5%
- **DRUG:** Meloxicam 0.09%
- **DRUG:** Sumatriptan 5%
- **DRUG:** Tizanidine 0.1%
- **DRUG:** Topiramate 2.5%
- **DRUG:** Capsaicin, USP 0.0375%
- **DRUG:** Menthol, NF 5.00 %

## Key facts

- **NCT ID:** NCT02403687
- **Lead sponsor:** Express Specialty Pharmacy
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-12
- **Final completion:** 2017-02
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2018-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02403687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02403687, "Prospective Analgesic Compound Efficacy (PACE) Study". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02403687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*